First Patient Dosed in AG-270 Phase 1 Trial in Lymphoma, Solid Tumors with MTAP Deletions
News
The first patient was dosed in a Phase 1 study of Agios Pharmaceuticals‘ investigational AG-270 in patients with solid tumors or lymphoma who have an MTAP deletion. A metabolic gene methylthioadenosine ... Read more